GLP-1 market heats up as companies vie for next-gen obesity drugs
Oct 31, 2024 · Since the FDA approval of Novo Nordisk’s Wegovy as a treatment for chronic weight management in 2021, followed by the approval of Ozempic the next year, demand for GLP-1 agonist drugs has rapidly grown.
$680M deal with CBC and Mubadala shifts UCB's strategy
Aug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company.
Adragos Pharma snaps up Baccinex to expand CDMO network
Nov 26, 2024 · Back in April this year, Raabe told Outsourcing Pharma that the company is on the lookout for strategic acquisitions with the mission to double or even triple its size in the coming years.. Adragos focuses its CDMO efforts on small molecule treatments, which are seeing a resurgence of interest even as biologics and cell and gene therapies generate big excitement in the biotech industry.
Merck acquires Modifi Biosciences in $1.3B cancer drug deal
Oct 24, 2024 · Modifi Biosciences, a spin out of Yale University founded in 2021, has been snapped up by Merck for $30 million paid upfront, and up to $1.3 billion in potential milestone payments.
How will the Biosecure Act impact the pharma industry?
Oct 8, 2024 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first proposed by the US government late last year due to concerns about national security and how genetic and other biological data could be misused by foreign adversarial governments with a focus on China.
Symbiosis unveils expanded facility at CPHI Milan 2024
Oct 2, 2024 · The event provides a great platform for the company to present its newest addition—a 20,000 sq ft facility in Stirling, UK, which the company says enhances Symbiosis' ability to support biopharma companies with high-quality manufacturing solutions.
FDA grants orphan drug designation to CervoMed’s dementia drug
Nov 28, 2024 · Speaking of the FDA’s recent decision for Neflamapimod, John Alam, CEO of CervoMed, said in a press release: “We are pleased to have received Orphan Drug Designation as it implicitly recognizes the scientific rationale and potential for Neflamapimod to treat this debilitating condition.
Decentralized clinical trials: Tech-driven solutions for patient access
Nov 13, 2024 · Allucent. Headquarters: Cary, North Carolina Founded: 2014 Allucent is a clinical research organization (CRO) with a strong focus on decentralized clinical trials. The company’s Patient Direct Trials platform is a customized all-in-one decentralized trial solution, including eCOAs, ePROs, telehealth, site workflows, analytics, and dashboards, integrations for sensors and wearables, eConsent ...
AbbVie acquires Nimble for oral peptides
Dec 17, 2024 · “The talented, passionate and dedicated team at Nimble has made great progress over the past few years and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline.”
How eCOA/ePRO is transforming clinical trials
Nov 25, 2024 · (Image: Getty/Spainter_vfx) Q: What trends do you see shaping eCOA/ePRO in the next year? SR: Personalization and adaptability are big ones.Patients want tailored experiences, so platforms will need to adapt to individual needs — whether that’s through language options, integration with personal devices, or customized notifications.